The first-in-human dose escalation, multi-centre trial aims to evaluate the safety and preliminary efficacy of the therapy.

(Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the first patient has been dosed in the pivotal Phase 3 OVATION 3 Study ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

The move has triggered a $75m milestone payment to Vir as part of its 2024 exclusive global licence agreement with Sanofi.

Vico Therapeutics announced that the first patient has been dosed in a phase 1/2a study evaluating VO659, an investigational antisense oligonucleotide for Huntington’s disease and ...

Technoderma Medicines has dosed its first patients in its phase 2a clinical trial of topical TDM-180935 ointment for the treatment of atopic dermatitis, the company announced in a press release ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...

U pstream Bio has dosed the first subject in the randomised Phase II trial of verekitug, an antibody antagonist targeting the thymic stromal lymphopoietin (TSLP) receptor, in individuals with chronic ...

Allay Therapeutics’ Japanese partner Maruishi Pharmaceutical has also dosed the first patient in January in a Phase I/II multi-center open-label safety study of ATX101 in Japan.

PRAGUE-- (BUSINESS WIRE)-- SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, announced today that it has dosed the first patients in the combination therapy arms of its ...

Transformative acquisition projected to generate up to an additional $7 million in annualized revenue in 2025 and further expand bottom line.Brings HACCP, GMP-certified, and FDA-registered manufacturi ...